Will GoodRX Stock Bounce Back?
GoodRX (NASDAQ:GDRX) tracks prescription drug prices and its model was…
Buy
65
ULBI Quote, Financials, Valuation and Earnings
Last price:
$8.83
Seasonality move
:
-0.68%
Day range:
$8.35 - $8.72
52-week range:
$4.07 - $12.40
Dividend yield:
0%
P/E ratio:
26.88x
P/S ratio:
0.83x
P/B ratio:
1.05x
Volume:
41.1K
Avg. volume:
153.7K
1-year change:
-26.87%
Market cap:
$143M
Revenue:
$164.5M
EPS (TTM):
$0.32
Analysts' Opinion
-
Consensus RatingUltralife has received a consensus rating of Buy. The company's average rating is a Buy based on 1 Buy rating, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $14.00, Ultralife has an estimated upside of 62.79% from its current price of $8.60.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $14.00 representing 100% downside risk from its current price of $8.60.
Fair Value
-
According to the consensus of 1 analyst, Ultralife has 62.79% upside to fair value with a price target of $14.00 per share.
ULBI vs. S&P 500
-
Over the past 5 trading days, Ultralife has underperformed the S&P 500 by -1.78% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Ultralife does not have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Ultralife has grown year-over-year revenues for 1 quarter straight. In the most recent quarter Ultralife reported revenues of $50.7M.
Earnings Growth
-
Ultralife earnings have been falling on a year-over-year basis for 4 quarters in a row. In the most recent quarter Ultralife reported earnings per share of $0.11.
Enterprise value:
188.1M
EV / Invested capital:
--
Price / LTM sales:
0.83x
EV / EBIT:
19.61x
EV / Revenue:
1.09x
PEG ratio (5yr expected):
0.08x
EV / Free cash flow:
10.67x
Price / Operating cash flow:
8.20x
Enterprise value / EBITDA:
13.31x
Gross Profit (TTM):
$43.6M
Return On Assets:
2.73%
Net Income Margin (TTM):
3.05%
Return On Equity:
3.96%
Return On Invested Capital:
3.22%
Operating Margin:
6.7%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Income Statement | ||||||
| Revenue | $133.4M | $168.7M | $173.3M | $41.9M | $50.7M | |
| Gross Profit | $29.9M | $43.2M | $43.6M | $11.5M | $12.7M | |
| Operating Income | $450K | $13.5M | $9.3M | $4.1M | $3.4M | |
| EBITDA | $5M | $19.2M | $14.1M | $5.1M | $4.8M | |
| Diluted EPS | -$0.01 | $0.64 | $0.32 | $0.18 | $0.11 | |
| Period Ending | 2021-03-31 | 2022-03-31 | 2023-03-31 | 2024-03-31 | 2025-03-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $63.5M | $69.1M | $81.4M | $94.3M | $101.5M | |
| Total Assets | $136.4M | $161.4M | $171.2M | $180.6M | $223.8M | |
| Current Liabilities | $16.6M | $20M | $29.2M | $23.4M | $31.5M | |
| Total Liabilities | $18.5M | $43.7M | $54.8M | $51.6M | $87.1M | |
| Total Equity | $117.9M | $117.6M | $116.4M | $128.9M | $136.6M | |
| Total Debt | $993K | $22M | $23.1M | $25.1M | $53.6M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $594K | $3.2M | $20.1M | -$81K | $3.4M | |
| Cash From Investing | -$1.8M | -$2.4M | -$50.5M | -$372K | -$895K | |
| Cash From Financing | $1.1M | $3.9M | $29M | $185K | -$687K | |
| Free Cash Flow | -$1.2M | $786K | $17.6M | -$453K | $2.5M | |
ULBI
Sector
Market Cap
$143M
$611.3M
Price % of 52-Week High
69.36%
81.21%
Dividend Yield
0%
0%
Shareholder Yield
--
2.28%
1-Year Price Total Return
-26.87%
-1.12%
Beta (5-Year)
0.995
0.761
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$8.70
200-day SMA
Buy
Level
$7.16
Bollinger Bands (100)
Buy
Level
4.72 - 7.74
Chaikin Money Flow
Sell
Level
-83.9K
20-day SMA
Buy
Level
$8.55
Relative Strength Index (RSI14)
Buy
Level
59.48
ADX Line
Sell
Level
18.97
Williams %R
Neutral
Level
-46.3458
50-day SMA
Buy
Level
$7.20
MACD (12, 26)
Buy
Level
2.36
25-day Aroon Oscillator
Buy
Level
48
On Balance Volume
Neutral
Level
11.6K
Financial Scores
Hold
Altman Z-Score
(Annual)
Level (1.9119)
Buy
CA Score
(Annual)
Level (0.7808)
Buy
Beneish M-Score
(Annual)
Level (-2.8388)
Sell
Momentum Score
Level (2)
Buy
Ohlson Score
Level (-0.0604)
Buy
Piotroski F Score
(Annual)
Level (5)
Buy
Quality Ratio Score
Level (5)
Buy
Fundamental Score
Level (7)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Ultralife Corp provides products and services ranging from power solutions to communications and electronics systems to customers across the globe in the government and defense, medical, safety and security, energy, and industrial sectors. The company designs, manufactures, installs, and maintains power and communications systems including rechargeable and non-rechargeable batteries, charging systems, communications and electronics systems and accessories, and custom-engineered systems. The company's segments include Battery and Energy Products, and Communications Systems. It generates maximum revenue from the Battery and Energy Products segment, and from the U.S. The Battery & Energy Products segment includes Lithium 9-volt, cylindrical, and various other non-rechargeable batteries.
Stock Forecast FAQ
In the current month, ULBI has received 1 Buy ratings 0 Hold ratings, and 0 Sell ratings. The ULBI average analyst price target in the past 3 months is $14.00.
-
Where Will Ultralife Stock Be In 1 Year?
According to analysts, the consensus estimate is that Ultralife share price will rise to $14.00 per share over the next 12 months.
-
What Do Analysts Say About Ultralife?
Analysts are divided on their view about Ultralife share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Ultralife is a Sell and believe this share price will drop from its current level to $14.00.
-
What Is Ultralife's Price Target?
The price target for Ultralife over the next 1-year time period is forecast to be $14.00 according to 1 Wall Street analyst, 1 of them rates the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is ULBI A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Ultralife is a Buy. 1 of 1 analysts rates the stock a Buy at this time.
-
How Can I Buy Shares Of ULBI?
You can purchase shares of Ultralife via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Ultralife shares.
-
What Is The Ultralife Share Price Today?
Ultralife was last trading at $8.83 per share. This represents the most recent stock quote for Ultralife. Yesterday, Ultralife closed at $8.60 per share.
-
How To Buy Ultralife Stock Online?
In order to purchase Ultralife stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will FCX Benefit From Tariffs?
Freeport-McMoRan (NYSE:FCX) is among the world’s largest producers of copper…
Can Levi Stock Double?
Levi Strauss (NYSE:LEVI) is among the oldest clothing brands in…
Stock Ideas
Buy
70
Is NVDA Stock a Buy?
Market Cap: $4.2T
P/E Ratio: 58x
Buy
62
Is MSFT Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 43x
Sell
40
Is AAPL Stock a Buy?
Market Cap: $3.1T
P/E Ratio: 35x
Alerts
Buy
82
SBET alert for Jul 17
SharpLink Gaming [SBET] is down 2.6% over the past day.
Buy
89
EXOD alert for Jul 17
Exodus Movement [EXOD] is down 4.14% over the past day.
Buy
60
U alert for Jul 17
Unity Software [U] is up 7.51% over the past day.
